Top Markets
#1 Siren Siren +44.69%
#2 Full Moon Full Moon +19.74%
#3 SODAX SODAX +17.22%
#4 Wrapped NXM Wrapped NXM +12.31%
#5 VVS Finance VVS Finance +11.53%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.92%
#7 Seeker Seeker +9.74%
#8 Helium Helium +9.54%
#9 Cryptopia Cryptopia +9.26%
#10 Zora Zora +7.54%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
Cybin Inc. Common Stock Cybin Inc. Common Stock

Cybin Inc. Common Stock

HELP
Rank in Stocks #11950
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Share Price
$10.30
Last synced: 2026-08-11
Market Cap
$638.32M
Change (1 day)
2.88%
Change (1 year)
-
Country
CA
Trade Cybin Inc. Common Stock (HELP)

Category

Healthcare
Revenue for Cybin Inc. Common Stock (HELP)
Revenue in Aug 2026 TTM: 0
According to Cybin Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cybin Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH